CY1111880T1 - Βελτιωμενο διαδερμικο θεραπευτικο συστημα για την αγωγη της νοσου του parkinson - Google Patents

Βελτιωμενο διαδερμικο θεραπευτικο συστημα για την αγωγη της νοσου του parkinson

Info

Publication number
CY1111880T1
CY1111880T1 CY20101100624T CY101100624T CY1111880T1 CY 1111880 T1 CY1111880 T1 CY 1111880T1 CY 20101100624 T CY20101100624 T CY 20101100624T CY 101100624 T CY101100624 T CY 101100624T CY 1111880 T1 CY1111880 T1 CY 1111880T1
Authority
CY
Cyprus
Prior art keywords
parkinson
disease
interderative
treatment
improved
Prior art date
Application number
CY20101100624T
Other languages
English (en)
Inventor
Thomas Lauterbach
Dietrich Wilhelm Schacht
Hans-Michael Wolff
Walter Müller
Original Assignee
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh
Publication of CY1111880T1 publication Critical patent/CY1111880T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει τη χρήση ενός βασιζόμενου σε σιλικόνη διαδερμικού θεραπευτικού συστήματος έχοντος εμβαδόν 10 έως 40 cm2 και περιέχοντος 0,1 έως 3,15 mg/cm2 ροτιγοτίνης ως δραστικό συστατικό, για την παρασκευή ενός φαρμάκου κατά της Parkinson το οποίο επιτυγχάνει μία βελτίωση, σε σύγκριση με μία εικονική αγωγή, της καταστάσεως ασθενών ανθρώπων με Parkinson, μετρούμενης σύμφωνα με την Ενοποιημένη Κλίμακα Αξιολογήσεως της νόσου του Parkinson (UPDRS), μέρη II και III, κατά 2 μονάδες ή περισσότερο μετά από χορήγηση επί μία χρονική περίοδο τουλάχιστον 7 εβδομάδων.
CY20101100624T 2001-05-08 2010-07-06 Βελτιωμενο διαδερμικο θεραπευτικο συστημα για την αγωγη της νοσου του parkinson CY1111880T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111110A EP1256340B1 (en) 2001-05-08 2001-05-08 Improved transdermal therapeutic system for the treatment of Parkinson's disease
EP02735338A EP1392256B1 (en) 2001-05-08 2002-05-06 Improved transdermal therapeutic system for the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
CY1111880T1 true CY1111880T1 (el) 2015-11-04

Family

ID=8177357

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100624T CY1111880T1 (el) 2001-05-08 2010-07-06 Βελτιωμενο διαδερμικο θεραπευτικο συστημα για την αγωγη της νοσου του parkinson

Country Status (17)

Country Link
EP (3) EP1256340B1 (el)
JP (1) JP2004528359A (el)
KR (1) KR100968293B1 (el)
CN (1) CN100457095C (el)
AT (2) ATE246919T1 (el)
AU (1) AU2002310805B8 (el)
CY (1) CY1111880T1 (el)
DE (2) DE60100595T2 (el)
DK (2) DK1256340T3 (el)
ES (2) ES2203563T3 (el)
HK (2) HK1049448B (el)
HU (1) HU229353B1 (el)
PT (2) PT1256340E (el)
RU (1) RU2273477C2 (el)
SI (1) SI1256340T1 (el)
WO (1) WO2002089777A1 (el)
ZA (1) ZA200209980B (el)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
US8246980B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
US8815215B2 (en) † 2003-08-15 2014-08-26 Colgate-Palmolive Company Hydrophobic tooth whitening system and methods of use
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
JP2008514376A (ja) * 2004-09-29 2008-05-08 シュウォーツ ファーマ インコーポレイテッド パーキンソン病のための経皮治療システム
WO2008146284A2 (en) * 2007-05-30 2008-12-04 Chemagis Ltd. Crystalline rotigotine base and preparation process therefor
MX2010005925A (es) 2007-11-28 2010-08-02 Ucb Pharma Gmbh Nueva forma polimorfico de rotigotina y proceso para la produccion.
DE102008060203A1 (de) 2008-12-07 2010-06-10 Dietrich Wilhelm Schacht Wirkstoffstabilisierende flächenförmige Vorrichtung
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
DE102009052972A1 (de) 2009-11-12 2011-09-15 Lts Lohmann Therapie-Systeme Ag Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm
EA025584B1 (ru) 2009-12-22 2017-01-30 ЮСиБи ФАРМА ГМБХ Поливинилпирролидон для стабилизации твердой дисперсии некристаллической формы ротиготина
US8729306B2 (en) 2010-02-05 2014-05-20 Ucb Pharma Gmbh Process for the preparation of nitrogen substituted aminotetralins derivatives
KR20130122721A (ko) 2010-06-25 2013-11-08 유씨비 파르마 게엠베하 질소 치환된 （ｓ）―５―알콕시―２―아미노테트랄린 유도체의 분리 방법
CN102475692A (zh) * 2010-11-29 2012-05-30 重庆医药工业研究院有限责任公司 一种防止雷沙吉兰挥发的透皮贴片
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
CN102499906B (zh) * 2011-10-12 2013-04-17 长春健欣生物医药科技开发有限公司 一种罗替戈汀盐酸盐或自由碱成膜凝胶制剂及其制备方法
DE102012013421A1 (de) 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
WO2013075823A1 (en) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system comprising rotigotine and crystallization inhibitor
DE102012013439A1 (de) 2012-07-03 2014-01-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
KR101558042B1 (ko) * 2012-07-05 2015-10-07 에스케이케미칼주식회사 로티고틴을 함유한 경피흡수제제
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
WO2014198422A1 (de) * 2013-06-14 2014-12-18 Tesa Labtec Gmbh Transdermales therapiesystem (tts) mit rotigotin
WO2015001012A1 (de) 2013-07-03 2015-01-08 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches system mit elektronischem bauteil
WO2015177204A1 (en) * 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
EP3145503A1 (en) 2014-05-20 2017-03-29 LTS Lohmann Therapie-Systeme AG Method for adjusting the release of active agent in a transdermal delivery system
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
ES2966170T3 (es) 2020-01-24 2024-04-18 Luye Pharma Switzerland Ag Sistema terapéutico transdérmico que comprende rotigotina y al menos un adhesivo de silicona no resistente a las aminas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
JPH0959153A (ja) * 1995-08-18 1997-03-04 Teisan Seiyaku Kk 硝酸イソソルビド含有貼付剤の製造方法
JP3628809B2 (ja) * 1996-06-10 2005-03-16 アルケア株式会社 薬剤徐放性医療用配合物及びその製造方法
JP3615620B2 (ja) * 1996-06-13 2005-02-02 積水化学工業株式会社 貼付剤
BR9906821A (pt) * 1998-01-09 2000-10-17 Mor Research Applic Ltd Composição farmacêutica e processo para melhorar a discinesia induzida por levodopa e discinesia tardia, e, uso de riluzol para a preparação de uma composição farmacêutica
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten
PT1256339E (pt) * 2001-05-08 2004-02-27 Lohmann Therapie Syst Lts Sistema terapeutico transdermico para doenca de parkinson que induz niveis plasmaticos altos de rotigotina

Also Published As

Publication number Publication date
DE60100595D1 (de) 2003-09-18
WO2002089777A1 (en) 2002-11-14
HK1049448B (zh) 2003-12-12
ES2344782T3 (es) 2010-09-07
DE60236078D1 (de) 2010-06-02
DE60100595T2 (de) 2004-06-24
HK1049448A1 (en) 2003-05-16
EP1256340A1 (en) 2002-11-13
ATE246919T1 (de) 2003-08-15
KR100968293B1 (ko) 2010-07-07
RU2273477C2 (ru) 2006-04-10
ZA200209980B (en) 2003-02-24
RU2003128642A (ru) 2005-03-27
EP1392256B1 (en) 2010-04-21
DK1256340T3 (da) 2003-12-01
AU2002310805B2 (en) 2005-09-08
AU2002310805B8 (en) 2006-01-12
HK1061194A1 (en) 2004-09-10
JP2004528359A (ja) 2004-09-16
HUP0302897A2 (hu) 2003-12-29
DK1392256T3 (da) 2010-08-02
HUP0302897A3 (en) 2005-02-28
EP1256340B1 (en) 2003-08-13
PT1256340E (pt) 2003-12-31
SI1256340T1 (en) 2003-12-31
EP1325742A1 (en) 2003-07-09
HU229353B1 (en) 2013-11-28
KR20030025941A (ko) 2003-03-29
ES2203563T3 (es) 2004-04-16
CN100457095C (zh) 2009-02-04
CN1462185A (zh) 2003-12-17
ATE464886T1 (de) 2010-05-15
PT1392256E (pt) 2010-07-13
EP1392256A1 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
CY1111880T1 (el) Βελτιωμενο διαδερμικο θεραπευτικο συστημα για την αγωγη της νοσου του parkinson
CY1109861T1 (el) Διαδερμικο θεραπευτικο συστημα για την ασθενεια του παρκινσον που προκαλει υψηλα επιπεδα πλασματος της ροτιγοτινης
CY1114139T1 (el) Πλακιδιο βουπρενορφινης για τη θεραπεια υποκαταστασης ναρκωτικων
CY1108384T1 (el) Διαδερμικη δοσολογια βουπρενορφινης για αναλγησια
DE60121301D1 (de) Flibanserin zur Behandlung extrapyramidaler Bewegungsstörungen
HUP0102728A2 (hu) Módszerek és transzdermális készítmények fájdalom csillapítására
CY1107452T1 (el) Διαδερμικη μορφη χορηγησης για τη θεραπεια του συνδρομου ανησυχων ποδιων
CY1108436T1 (el) Χορηγηση καψαϊκινοειδων
CY1112260T1 (el) Σκευασματα υδροκωδονης ελεγχομενης απελευθερωσης
FI7341U1 (fi) Transdermaalinen laastari fentanyylin antamiseksi
CY1105608T1 (el) Φαρμακευτικες συνθεσεις παραγωγου του λευκοχρυσου
CY1112689T1 (el) Συνθεση για τη βελτιωση της γνωσης και της μνημης
PT1383752E (pt) 3-piperidinopropiofenonas deuteradas assim como farmacos contendo estes compostos
DE50112452D1 (de) Transdermales therapeutisches system zur behandlung des restless-legs-syndroms
JP2004506682A5 (el)
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
ATE297732T1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
CY1106129T1 (el) Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος
TR200301916T4 (tr) Rotigotinin yüksek plazma seviyelerini kapsayan parkinson hastalığına yönelik transdermal terapötik sistem.
DE10293092D2 (de) Schilddrüsentherapeutika
CY1105347T1 (el) Η χρηση της προπιονυλο l-καρνιτινης ή ενος απο τα φαρμακολογικα αποδεκτα αλατα της για την παρασκευη ενος φαρμακου για τη θepαπευτικη αντιμετωπιση της νοσου του peyronie